Corporate

Management

• Mel Kronick, PhD – President & CEO
• Conrad Lichtenstein, PhD – Vice President, Research & Development
• Frank Massam, PhD – Vice President, Business Development

Board of Directors

• Sam Eletr, PhD – Chairman of PGT; also Chairman of the Board of SpinX Technologies and of Domain Therapeutics
• Mel Kronick, PhD – President & CEO of PGT, former R&D Manager and Chief Scientist for Genomics at Agilent Technologies,  R&D Manager at Applied Biosystems
• Mark Treherne, PhD – Former R&D Manager at Pfizer, founder and CEO of Cambridge Drug Discovery and board member of biotech companies including Senexis and Xention
• Bernard Daugeras, PhD – Managing Partner, Auriga Partners
• Stephane Mery, DVM – Investment Director, Beringea Ltd

Scientific Advisors

• Sydney Brenner, MD, DPhil - Professor, Kings College, Cambridge University; Distinguished Professor, Salk Institute; Honorary Citizen of Singapore and former Chairman of Singapore’s Scientific Advisory Board; Nobel Prize in Physiology or Medicine in 2002
• Philip Goelet, PhD - Venture Capitalist with Red Abbey LLC (which he co-founded); founder and CEO of Molecular Tool; former board member of GeneScreen

Investors

• The Wellcome Trust Ltd.
• Auriga Partners
• Beringea Ltd.
• Compass Genetics Investors LLC